Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2024-10-17 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于全资子公司依替巴肽原料药获批上市的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the approval for marketing of a raw material drug (Eptifibatide) by its wholly-owned subsidiary. It includes details about the drug registration, approval by the National Medical Products Administration, and the impact on the company. The document is short (931 characters) and is an announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or regulatory certifications. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category about product approval and company impact, which aligns with Regulatory Filings (RNS).
2024-10-17 Chinese
关于设立合资公司并完成工商注册登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. about the establishment of a joint venture company and completion of its business registration. It details the joint venture's capital structure, shareholders, business scope, and the strategic purpose and risks of the cooperation. There are no financial statements, quarterly or annual results, or audit information presented. The document is a corporate announcement about a capital investment and business development activity, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Capital/Financing Update (CAP) because it concerns the company's investment in a joint venture and related capital contributions.
2024-10-10 Chinese
筹融资管理制度
Capital/Financing Update Classification · 95% confidence The document is titled as a "筹融资管理制度" which translates to "Financing Management System" or "Capital/Financing Management Policy". It outlines the company's internal policies, responsibilities, procedures, and controls related to financing activities such as bank loans, bond issuance, stock issuance, and other financing methods. It references relevant laws and regulations, internal approval processes, and management principles. The document is a governance or policy document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a notice or announcement of a report. It is a detailed internal governance document related to financing management. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3515 characters, which is consistent with a policy document rather than a full report or announcement. Confidence is high given the clear focus on financing management policies and procedures.
2024-09-30 Chinese
对外担保管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for external guarantees by 安徽安科生物工程（集团）股份有限公司. It details the company's policies, procedures, and responsibilities regarding external guarantees, including legal compliance, approval processes, risk management, disclosure obligations, and responsibilities of directors and management. There are references to regulatory requirements and internal governance but no financial statements, earnings data, or report publication announcements. The content is focused on governance and internal control policies rather than financial results or shareholder meeting materials. Therefore, this document fits best under Governance Information (CGR), as it outlines the company's governance practices related to external guarantees.
2024-09-30 Chinese
关于控股子公司收到安徽省药品监督管理局通知的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding a notification received from the Anhui Provincial Drug Administration about a GMP compliance inspection of its controlling subsidiary. It details the inspection results, the subsidiary's production suspension, corrective actions, and the expected impact on the company. The document is a regulatory announcement about operational and compliance issues, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is not a report publication announcement or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-30 Chinese
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '安徽安科生物工程（集团）股份有限公司 对外投资管理制度' which translates to 'Anhui Anke Biotechnology (Group) Co., Ltd. External Investment Management System'. It is a detailed internal policy document outlining the company's procedures, responsibilities, decision-making authority, and disclosure requirements related to external investments. The content includes references to company law, stock exchange listing rules, board and shareholder meeting approvals, investment thresholds, and internal controls. There is no indication that this is a financial report, audit, earnings release, or any form of regulatory filing. It is a governance-related document describing internal rules and governance practices concerning external investments. Therefore, the most appropriate classification is Governance Information (CGR). The document length (6586 characters) and detailed procedural content support this classification with high confidence.
2024-09-30 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.